Literature DB >> 23546555

Adherence to repeat fecal occult blood testing in an urban community health center network.

David T Liss1, Anita Petit-Homme, Joe Feinglass, David R Buchanan, David W Baker.   

Abstract

Annual fecal occult blood testing (FOBT) has the potential to reduce colorectal cancer mortality, but in practice it is challenging to complete FOBT every year. Repeat FOBT adherence may be especially low in community health center (CHC) settings, where many patients face barriers to annual FOBT completion. We conducted a retrospective cohort analysis to investigate adherence to annual FOBT in an urban CHC network that serves a predominantly Spanish-speaking, uninsured adult patient population. This study used data from the two-year period between January 2010 and December 2011, and included adults aged 50-74 who completed a screening FOBT with a negative result during the first 6 months of 2010. We examined whether each patient completed a second FOBT between 9 and 18 months after the initial negative FOBT, and tested whether repeat FOBT adherence was associated with patient characteristics or the number of clinic visits after the initial negative FOBT. Only 69 of 281 included patients completed repeat FOBT (24.6 % adherence), and none of 62 patients (0 %) with 0 clinic visits completed repeat FOBT. We detected no significant differences in adherence by age, sex, preferred language, insurance status, or number of chronic conditions. In multivariable regression, the adjusted relative risk of repeat FOBT was 1.66 (95 % CI 1.09-2.54; p = 0.02) among patients with 3 or more clinic visits (referent: patients with 1-2 visits). The observed low rate of adherence greatly diminishes the effectiveness of FOBT in reducing CRC mortality. Findings demonstrate the need for systems-based interventions that increase adherence without requiring face-to-face encounters.

Entities:  

Mesh:

Year:  2013        PMID: 23546555     DOI: 10.1007/s10900-013-9685-x

Source DB:  PubMed          Journal:  J Community Health        ISSN: 0094-5145


  24 in total

1.  A modified poisson regression approach to prospective studies with binary data.

Authors:  Guangyong Zou
Journal:  Am J Epidemiol       Date:  2004-04-01       Impact factor: 4.897

2.  Racial disparities in stage-specific colorectal cancer mortality: 1960-2005.

Authors:  Samir Soneji; Shally Shalini Iyer; Katrina Armstrong; David A Asch
Journal:  Am J Public Health       Date:  2010-08-19       Impact factor: 9.308

3.  Automated telephone calls improved completion of fecal occult blood testing.

Authors:  David M Mosen; Adrianne C Feldstein; Nancy Perrin; A Gabriela Rosales; David H Smith; Elizabeth G Liles; Jennifer L Schneider; Jennifer E Lafata; Ronald E Myers; Michael Kositch; Thomas Hickey; Russell E Glasgow
Journal:  Med Care       Date:  2010-07       Impact factor: 2.983

Review 4.  Two decades of declining cancer mortality: progress with disparity.

Authors:  Tim Byers
Journal:  Annu Rev Public Health       Date:  2010       Impact factor: 21.981

5.  Longitudinal adherence with fecal occult blood test screening in community practice.

Authors:  Joshua J Fenton; Joann G Elmore; Diana S M Buist; Robert J Reid; Daniel J Tancredi; Laura-Mae Baldwin
Journal:  Ann Fam Med       Date:  2010 Sep-Oct       Impact factor: 5.166

6.  Predictors of colorectal cancer screening participation in the United States.

Authors:  George N Ioannou; Michael K Chapko; Jason A Dominitz
Journal:  Am J Gastroenterol       Date:  2003-09       Impact factor: 10.864

7.  Longitudinal adherence to fecal occult blood testing impacts colorectal cancer screening quality.

Authors:  Ziad F Gellad; Karen M Stechuchak; Deborah A Fisher; Maren K Olsen; Jennifer R McDuffie; Truls Ostbye; William S Yancy
Journal:  Am J Gastroenterol       Date:  2011-02-08       Impact factor: 10.864

8.  Understanding racial and ethnic disparities in colorectal cancer screening: Behavioral Risk Factor Surveillance System, 2002 and 2004.

Authors:  Natalie D Crawford; Camara P Jones; Lisa C Richardson
Journal:  Ethn Dis       Date:  2010       Impact factor: 1.847

9.  A randomized controlled trial of the impact of targeted and tailored interventions on colorectal cancer screening.

Authors:  Ronald E Myers; Randa Sifri; Terry Hyslop; Michael Rosenthal; Sally W Vernon; James Cocroft; Thomas Wolf; Jocelyn Andrel; Richard Wender
Journal:  Cancer       Date:  2007-11-01       Impact factor: 6.860

10.  Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force.

Authors:  Ann G Zauber; Iris Lansdorp-Vogelaar; Amy B Knudsen; Janneke Wilschut; Marjolein van Ballegooijen; Karen M Kuntz
Journal:  Ann Intern Med       Date:  2008-10-06       Impact factor: 25.391

View more
  16 in total

1.  Third Annual Fecal Occult Blood Testing in Community Health Clinics.

Authors:  Connie L Arnold; Alfred Rademaker; Michael S Wolf; Dachao Liu; Jill Hancock; Terry C Davis
Journal:  Am J Health Behav       Date:  2016-05

2.  Impact of continued mailed fecal tests in the patient-centered medical home: Year 3 of the Systems of Support to Increase Colon Cancer Screening and Follow-Up randomized trial.

Authors:  Beverly B Green; Melissa L Anderson; Jessica Chubak; Sharon Fuller; Richard T Meenan; Sally W Vernon
Journal:  Cancer       Date:  2015-10-21       Impact factor: 6.860

3.  Decrease in Incidence of Colorectal Cancer Among Individuals 50 Years or Older After Recommendations for Population-based Screening.

Authors:  Caitlin C Murphy; Robert S Sandler; Hanna K Sanoff; Y Claire Yang; Jennifer L Lund; John A Baron
Journal:  Clin Gastroenterol Hepatol       Date:  2016-09-05       Impact factor: 11.382

4.  A Systematic Review of Repeat Fecal Occult Blood Tests for Colorectal Cancer Screening.

Authors:  Caitlin C Murphy; Ahana Sen; Bianca Watson; Samir Gupta; Helen Mayo; Amit G Singal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-11-18       Impact factor: 4.254

5.  Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.

Authors:  Amit G Singal; Samir Gupta; Celette Sugg Skinner; Chul Ahn; Noel O Santini; Deepak Agrawal; Christian A Mayorga; Caitlin Murphy; Jasmin A Tiro; Katharine McCallister; Joanne M Sanders; Wendy Pechero Bishop; Adam C Loewen; Ethan A Halm
Journal:  JAMA       Date:  2017-09-05       Impact factor: 56.272

6.  Longitudinal predictors of colorectal cancer screening among participants in a randomized controlled trial.

Authors:  Caitlin C Murphy; Sally W Vernon; Nicole M Haddock; Melissa L Anderson; Jessica Chubak; Beverly B Green
Journal:  Prev Med       Date:  2014-06-15       Impact factor: 4.018

7.  Strategies to improve repeat fecal occult blood testing cancer screening.

Authors:  Terry C Davis; Connie L Arnold; Charles L Bennett; Michael S Wolf; Cristalyn Reynolds; Dachao Liu; Alfred Rademaker
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-11-05       Impact factor: 4.254

8.  Adherence to Competing Strategies for Colorectal Cancer Screening Over 3 Years.

Authors:  Peter S Liang; Chelle L Wheat; Anshu Abhat; Alison T Brenner; Angela Fagerlin; Rodney A Hayward; Jennifer P Thomas; Sandeep Vijan; John M Inadomi
Journal:  Am J Gastroenterol       Date:  2015-11-03       Impact factor: 10.864

9.  Outreach invitations for FIT and colonoscopy improve colorectal cancer screening rates: A randomized controlled trial in a safety-net health system.

Authors:  Amit G Singal; Samir Gupta; Jasmin A Tiro; Celette Sugg Skinner; Katharine McCallister; Joanne M Sanders; Wendy Pechero Bishop; Deepak Agrawal; Christian A Mayorga; Chul Ahn; Adam C Loewen; Noel O Santini; Ethan A Halm
Journal:  Cancer       Date:  2015-11-04       Impact factor: 6.860

10.  Adherence to colorectal cancer screening measured as the proportion of time covered.

Authors:  Caitlin C Murphy; Bianca M Sigel; Edward Yang; Celette Sugg Skinner; Ethan A Halm; Samir Gupta; Joanne M Sanders; Katharine McCallister; Amit G Singal
Journal:  Gastrointest Endosc       Date:  2018-02-23       Impact factor: 9.427

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.